-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hidradenitis suppurativa (HS) is a chronic recurrent hair follicle inflammatory skin disease, manifested by deep pain, nodules, abscesses, sinus and scar formation, most often confined to the armpits, groin, and anogenital area.
Recently, researchers investigated the therapeutic effect of adalimumab combined with extensive resection on patients with HS
The SHARPS trial is a phase IV clinical study investigating the combined treatment of adalimumab and surgery in the treatment of HS.
Each group contained 103 patients, including 106 female patients, with an average age of 37.
In the 12th week, 49 of the 103 patients in the adalimumab treatment group achieved a clinical response to HS in all parts of the body, while only 35 patients in the placebo group (48% vs 34%) in the 12th week, adalimumab 49 of the 103 patients in the treatment group achieved clinical response to HS in all parts of the body, while only 35 (48% vs 34%) in the placebo group were infected
Studies believe that adalimumab, as an auxiliary means of surgical treatment for patients with moderate to severe hidradenitis suppurativa, can significantly improve the prognosis of patients
Adalimumab as an adjunct in the surgical treatment of severe hidradenitis suppurativa patients can significantly improve the prognosis of adalimumab as severe suppurative hidradenitis surgery in patients with aids can significantly improve the prognosis of patients
Original source:
Original source:Falk G.
Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa The SHARPS Randomized Clinical Trial.
Leave a message here
